Psyence Biomedical Ltd. (Nasdaq: PBM) has executed a share-for-share exchange transaction following PsyLabs' exercise of its put option rights. Under the agreement, Psyence will issue 1,146,159 common shares valued at $5 million in exchange for 2,900 PsyLabs shares, positioning PsyLabs as a significant stakeholder with approximately 49.98% ownership in the company upon closing.
The transaction is scheduled to conclude on February 25, 2026, and represents a strategic consolidation of the companies' interests. According to the announcement, the exchange is designed to strengthen supply chain security for pharmaceutical-grade psychedelic compounds, a critical component as Psyence advances its clinical development programs in the emerging psychedelic medicine sector.
This equity transaction underscores the capital structure dynamics within Psyence BioMed as it continues to develop its pipeline of psychedelic-based therapeutics. The near-majority stake held by PsyLabs following the exchange reflects the deeper operational integration between the entities in addressing regulatory and manufacturing requirements for controlled substance production.